| Species |
Human |
| Protein Construction |
Mesothelin (Glu296-Gly580)
Accession # Q13421 |
hFc |
| N-term |
C-term |
|
| Purity |
> 90% as analyzed by SDS-PAGE |
| Endotoxin Level |
≤ 1 EU/μg of protein by gel clotting method |
| Expression System |
HEK 293 |
| Apparent Molecular Weight |
~66 kDa, on SDS-PAGE under reducing condition. |
| Formulation |
Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O or PBS up to 100 μg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
Lane 1: 2 μg of Mesothelin, hFc, Human, reducing(R)
> 95% as analyzed by SDS-PAGE
| Target Background |
Mesothelin, also known as MSLN, is a 40 kDa protein that is expressed in mesothelial cells. It has been reported that this protein is over expressed in several human tumors, including mesothelioma, ovarian cancer, pancreatic adenocarcinoma, lung adenocarcinoma, and cholangiocarcinoma. Mesothelin can bind MUC16 (also known as CA125), indicating that the interaction of mesothelin and MUC16 may contribute to the implantation and peritoneal spread of tumors by cell adhesion. Since mesothelin is overexpressed in several cancers and is immunogenic, the protein could be exploited as tumor marker or as the antigenic target of a therapeutic cancer vaccine. |
| Synonyms |
MSLN; CAK1 antigen; CAK1; megakaryocyte potentiating factor; Mesothelin; MPF; MPFSMRP; Pre-pro-megakaryocyte-potentiating factor; SMR; soluble MPF mesothelin related protein |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
